HCW Biologics Files 8-K for Material Agreement

TL;DR

HCW Biologics signed a material definitive agreement on 8/14/25. 8-K filed.

AI Summary

HCW Biologics Inc. filed an 8-K on August 15, 2025, reporting an entry into a material definitive agreement on August 14, 2025. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Miramar, Florida.

Why It Matters

This filing indicates a significant new agreement for HCW Biologics, which could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing of an 8-K for a material definitive agreement suggests a significant event that could carry inherent business risks.

Key Numbers

• 001-40591 — Commission File Number (Identifies the company's filing with the SEC)
• 82-5024477 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• HCW Biologics Inc. (company) — Registrant
• August 14, 2025 (date) — Date of earliest event reported
• August 15, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Miramar, Florida (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
• $20,000,000 — ion to purchase from the Company, up to $20,000,000 (the "Maximum Commitment Amount") worth

Filing Documents

• hcwb-20250814.htm (8-K) — 45KB
• hcwb-ex10_1.htm (EX-10.1) — 28KB
• 0000950170-25-109139.txt ( ) — 180KB
• hcwb-20250814.xsd (EX-101.SCH) — 24KB
• hcwb-20250814_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported on February 21, 2025, HCW Biologics Inc. (the "Company,", "we," "us," or "our") and Square Gate Capital Master Fund, LLC- Series 4 (the "Investor") entered into an Equity Purchase Agreement (the "ELOC EPA") pursuant to which the Company has the right, but not the obligation, to sell to the Investor, and the Investor will have the obligation to purchase from the Company, up to $20,000,000 (the "Maximum Commitment Amount") worth of the Company's shares of common stock, at the Company's sole discretion, over the 36-month period following its effective date (the "Put Shares"), subject to certain conditions precedent and other limitations. On August 14, 2025, the Company and the Investor entered into a First Amendment to the ELOC EPA (the "First Amendment") to provide a mechanism for submission by the Company and acceptance by the Investor of Put Notices under the ELOC EPA pursuant to which the Investor and the Company may agree to and execute multiple purchases and sales of Put Shares on the same trading day. Under the First Amendment, among other things, the purchase price of the intraday Put Shares will be the lowest traded price during a specified shortened valuation time period. The foregoing summary of certain terms of the ELOC EPA and the First Amendment does not purport to be complete.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 First Amendment to Equity Purchase Agreement, dated August 14, 2025, between the Company and Square Gate Capital Master Fund, LLC- Series 4 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: August 15, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR